NSG™ Variants by Research Area

Immunology

• NSG™ HLA Class I transgenic strains (009617 and 014570), expressing A2 haplotypes 
  • Permit HLA restriction and enhance immune responses of human CD8 T cells (Strowig, et al. 2009; Shultz, et al. 2010)
• NSG™ HLA Class II transgenic strains, expressing DR1 (012479) and DR4 (017637) haplotypes
  • Show enhanced antibody responses, and human CD4 T cells interact more effectively with human antigen presenting cells. A NRG DR4 transgenic strain, “DRAG” (017914), is accessible to for-profit entities (Danner R, et al. 2011)
• NSG™ transgenic human membrane-bound Kit ligand (017830)

  • Improved myeloid engraftment (especially mast cells) and do not require pre-conditioning irradiation before engrafting human hematopoietic stem cells (Brehm, et al. 2012; Takagi, et al. 2012)

• NSG™ transgenic human IL-3, CSF2, Kit ligand (013062)
  • Supports higher levels of human myeloid cell engraftment (Miller, et al. 2013)
• NOD Rag gamma (NRG) (007799)
  
  • Radiation-resistant alternative to NSG™ mice
  • Equally effective at engrafting human hematopoietic stem cells and undergoing multilineage hematopoiesis as NSG™ (Pearson, et al. 2008)
• NSG™ expressing EGFP (021937)
  
  • Expresses EGFP in all cells of the embryo and adult.
  • Facilitates visualization of allogeneic and xenogeneic grafts
• NSG™ expressing human IL15 cytokine (030890) (030890)
  • Improved function and abundance of human NK cells following CD34 humanization (Brehm, et al. 2018)
• NSG™ without MHC class I or class II molecules (025216)
  • Most resistant to xeno-GVHD of all NSG variants (Brehm, et al. 2018)
• NSG™ with Kit mutation (026622)
  • Can be humanized with CD34 cells in the absence of preconditioning irradiation (McIntosh, et al. 2015)

HIV & other infectious diseases

• NSG™ HLA Class I transgenic strains (009617 and 014570), expressing A2 haplotypes
  
  • Allow HLA restriction of developing human CD8 cells in humanized models, and provide improved platforms for viral infection and vaccine models (Strowig, et al. 2009; Shultz, et al. 2010)
  • Antibody responses improved in a Dengue virus infection model (Jaiswal, et al. 2012)
• NSG™ HLA Class II transgenic strains, expressing DR1 (012479) and DR4 (017637) haplotypes
  
  • Allow HLA restriction of developing human CD4 cells and improve interactions with antigen-presenting cells;
  • Enhanced IgG responses
• NSG™ mice lacking MHC class I, NSG™ B2m (010636) and NSG™ (KbDb ) null (023848)
  
  • Enable longer studies following human PBMC engraftment (King, et al. 2008 and Covassin, et al. 2013)

Cancer

• NSG™ transgenic human IL-3, CSF2, Kit ligand (013062)
  
  • Show enhanced patient-derived acute myeloid leukemia engraftment (Wunderlich, et al. 2010)
• NSG™ Hprt mice (012480)
  
  • Facilitates isolation of human cancer cells from mouse stroma in vitro, and enable establishment of new patient-derived cell lines (Kamiyama, et al. 2013)
• NSG™ expressing EGFP (021937)
  
  • Expresses EGFP in all cells of the embryo and adult
  • Facilitates visualization of allogeneic and xenogeneic grafts

Transplantation research

• NSG™ without MHC class I or class II molecules (025216)
  • Most resistant to xeno-GVHD of all NSG variants (Brehm, et al. 2018) 
• NSG™ lacking MHC class I, NSG™ B2m (010636) and NSG™ (K^b ) null (023848)
  
  • Enable longer studies following human PBMC engraftment (King, et al. 2008 and Covassin, et al. 2013) 
• NSG™ lacking MHC class II (021885)
  
  • Resistant to xenogenic graft-versus-host-disease (Covassin, et al. 2011)
• NSG™ expressing EGFP (021937)
  
  • Expresses EGFP in all cells of the embryo and adult
  • Facilitates visualization of allogeneic and xenogeneic grafts
• NSG™-PiZ, with AAT deficiency (028842)
  • Allows stable engraftment of human and allogeneic mouse hepatocytes (Borel, et al. 2017)

Diabetes

• NRG Akita (014568)
  
  • Spontaneously develop hyperglycemia and allow engraftment of human pancreatic islets and stem cell therapies for Type 1 Diabetes (Brehm, et al. 2010)